Juvenile idiopathic arthritis was formerly known as juvenile rheumatoid arthritis or juvenile chronic arthritis.
It presents as chronic joint swelling, pain with functional limitation for at least 6 weeks of unknown cause that starts before 16 year of age.
It is the most common autoimmune-autoinflammatory disease in children.
Around half of the children with juvenile idiopathic arthritis may have active disease until adulthood.
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Juvenile idiopathic arthritis in children carries a heightened risk of developing autoimmune diseases—such as rheumatoid arthritis, systemic lupus erythematosus and ankylosing spondylitis, among others—in adulthood, as reported in a recent study.
Rituximab appears to be effective in the treatment of children with juvenile idiopathic arthritis (JIA) who have not responded to a tumour necrosis factor inhibitor, a study has shown. Moreover, serious infection rates are low.
Treatment with canakinumab yields a rapid, substantial improvement in disease activity in children with systemic juvenile idiopathic arthritis (sJIA), according to long-term extension data from two phase III pivotal trials. Furthermore, response is sustained for up to 5 years, allowing dose reduction or even discontinuation of glucocorticoids without raising new safety concerns.
Among children with juvenile idiopathic arthritis, the risk of developing uveitis is not greater in those treated with etanercept than in those receiving methotrexate, according to a study presented at the European League Against Rheumatism (EULAR) 2018 Congress.
Abnormalities on ultrasound (US) examination may predict relapse in juvenile idiopathic arthritis (JIA) at the individual level, with a recent study showing that signs of inflammation on US are associated with about a fourfold increase in the risk of flare.
Exposure to ozone (O3) in the second year of life and cigarette smoke (intrauterine and after birth) and maternal occupational exposure may increase the risk of juvenile idiopathic arthritis (JIA), suggests a recent study.
New drug applications approved by US FDA as of 16 - 31 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Golimumab appears to induce rapid, clinically meaningful improvements in children with active polyarticular-course juvenile idiopathic arthritis (polyJIA), according to the results of a trial that did not meet its primary endpoint.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS JPOG - Malaysia digital copy today!
Short-term daily consumption or probiotic lozenges containing Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis BB-12 confers benefits for gingival health, as well as reduces the plaque carriage of periodontal pathogens, in adolescent males, a study has shown.
Intraoperative epidural analgesia, perioperative opioid and total dose of volatile agent appear to show some “clinically meaningful associations” with relapse-free survival (RFS) in children with solid organ tumour, particularly in paediatric sarcoma patients, according to a Singapore study. However, no statistically significant association exists between epidural use and an improved RFS.